Sandra Algaze
Medical Oncology · Los Angeles, CANPI 1861886707
Payments from drug & device makers
Across 74 payments — averaging $1479.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$62K
- AbbVie$30K
- Merck$9K
- E.r. Squibb & Sons, L.L.C.$4K
- Incyte Corporation$3K
- Amgen$414
- plus $1K from 15 others
What the payments were for
- Consulting fees$6,25572%
- Travel & lodging$3854%
- Food & beverage$2,01423%
- Education$260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $61,516 |
| AbbVie | 5 | $30,084 |
| Merck | 2 | $9,385 |
| E.r. Squibb & Sons, L.L.C. | 1 | $3,780 |
| Incyte Corporation | 13 | $3,241 |
| Amgen | 13 | $414 |
| Bristol Myers Squibb | 6 | $349 |
| Sobi, Inc | 5 | $123 |
| Sanofi | 5 | $106 |
| Lilly USA, LLC | 3 | $72 |
| Johnson & Johnson | 3 | $70 |
| AstraZeneca(2 entities) | 3 | $68 |
| EMD Serono, Inc. | 1 | $64 |
| Caris MPI, Inc. | 1 | $35 |
| Teva Pharmaceuticals USA, Inc. | 1 | $24 |
| Beigene USA, Inc. | 1 | $23 |
| Blueprint Medicines Corporation | 1 | $21 |
| Bayer | 1 | $20 |
| Jazz Pharmaceuticals Inc. | 1 | $20 |
| Genentech USA, Inc. | 1 | $20 |
| Agios Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$109,448 in reported general payments places this provider in the 55th percentile of 379 medical oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZenpepLipase/Protease/Amylase | 13 | $9,028 |
| EliquisApixaban | 11 | $6,345 |
| Ondansetron OdtOndansetron | 15 | $320 |
| LoperamideLoperamide Hcl | 14 | $216 |
| Triamcinolone Acetonide | 12 | $126 |
| Omeprazole | 11 | $73 |
| Furosemide | 21 | $70 |
| Amlodipine Besylate | 11 | $34 |
| Prednisone | 14 | $30 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Los Angeles
- Sarmad SadeghiLos Angeles$26.1M
- Heinz-Josef LenzLos Angeles$11.6M
- Anthony El-KhoueiryLos Angeles$10.5M
- Stephen LiuLos Angeles$8M
- Mark AgulnikLos Angeles$5M
- David QuinnLos Angeles$4M
- Daphne StewartLos Angeles$4M
- Patricia YoungLos Angeles$3.1M
- David TranLos Angeles$3.1M
- Syma IqbalLos Angeles$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.